Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis

Journal of Medical Economics

Volumn 14, Issue 5, 2011, Pages 617-627

  O'Day, Ken ^a   Meyer, Kellie ^a   Miller, Ross M ^b   Agarwal, Sonalee ^c   Franklin, Meg ^a,d  

^a XCENDA   (United States)

^b CERNER CORPORATION   (United States)

^c BIOGEN   (United States)

^d PRESBYTERIAN COLLEGE   (United States)

Author keywords

Cost effectiveness; Economic; Fingolimod; Multiple sclerosis; Natalizumab

Indexed keywords

FINGOLIMOD; NATALIZUMAB;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG ADMINISTRATION; DRUG COST; DRUG MONITORING; HUMAN; MULTIPLE SCLEROSIS; PATIENT ATTITUDE; POPULATION MODEL; RELAPSE; SENSITIVITY ANALYSIS; UNITED STATES;

ANTIBODIES, MONOCLONAL, HUMANIZED; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; RECURRENCE; SPHINGOSINE; UNITED STATES;

EID: 80052767484     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.602444     Document Type: Article

References (43)

1. National Multiple Sclerosis Society. Who gets MS? Available at: Http://www.nationalmssociety.org/index.aspx [Last accessed 10 December 2010]
2. Wingerchuck DM, Weinshenker BG. Multiple sclerosis: Epidemiology, genetics, classification, natural history, and clinical outcome measures. Adv Mult Scler 2000;10:611-23
3. Ryan M, Piascik P. Providing pharmaceutical care to the multiple sclerosis patient. J Am Pharm Assoc 2002;42:753-67
4. Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-25
5. Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52
6. Asche CV, Singer ME, Jhaveri M, et al. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm 2010;16:703-12
7. Pope GC, Urato CJ, Kulas ED, et al. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology 2002;58:37-43
8. Kunze AM, Gunderson BW, Gleason PP, et al. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs-pharmacy and medical benefit spending from 2004 through 2007. J Manag Care Pharm 2007;13:799-806
9. Schafer JA, Gunderson BW, Gleason PP. Price increases and new drugs drive increased expenditures for multiple sclerosis. J Manag Care Pharm 2010; 16:713-17
10. O'Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003;3:17-28
11. US Bureau of Labor Statistics. Consumer Price Index-July 2010. Washington, DC: US Bureau of Labor Statistics
12. Kieseier BC, Stüve O. A critical appraisal of treatment decisions in multiple sclerosis-old versus new. Nat Rev Neurol 2011;7:255-62. [Epub 2011 Apr 5]
13. Gilenya (fingolimod) [package insert]. East Hanover, NJ: Novartis, 2010
14. Gilenya Risk Evaluation and Mitigation Strategy (REMS). Novartis Pharmaceuticals Corporation. Approved REMS dated September 21, 2010
15. Cohen JA, Barkhof F, Comi G, et al; for the TRANSFORMS study group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. NEJM 2010;362:402-15
16. Comi G, O'Conner P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010;16:197-207
17. Portaccio E. Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis. Core Evidence 2010;6:13-21
18. Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009;15:543-55
19. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: A Markov model based on long-term clinical data. J Manag Care Pharm 2007;13:245-61
20. Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics 2008;26:617-27
21. Chiao E, Meyer K. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis. Curr Med Res Opin 2009; 25:1445-54
22. Tysabri (natalizumab) [package insert]. Cambridge, MA, USA: Biogen Idec, Inc., 2010
23. Avonex [package insert]. Cambridge, MA, USA: Biogen Idec, Inc., 2008
24. Betaseron [package insert]. Montville, NJ, USA: Bayer HealthCare Pharmaceuticals Inc., 2010
25. Copaxone [package insert]. Kansas City, MO, USA: Teva Neuroscience, Inc., 2009
26. Extavia [package insert]. East Hanover, NJ, USA: Novartis Pharmaceuticals Corporation, 2009
27. Rebif [package insert]. Rockland, MA, USA: Serono, Inc., 2009
28. Joyce AT, Iacoviello JM, Nag S, et al. End-stage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care 2004;27:2829-35
29. Polman CH, O'Connor PW, Havrdova E, et al; AFFIRM Investigators. A randomized placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
30. Kappos L, Radue W, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362:387-401
31. Biogen Idec Med Info. PML incidence in patients receiving Tysabri. Available at: Https://medinfo.biogenidec.com [registration required] [Last accessed 27 January 2011]
32. Campbell DE, Lynn J, Louis TA, et al. Medicare program expenditures associated with hospice use. Ann Intern Med 2004;140:269-77
33. Centers for Medicare & Medicaid Services. Physician Fee Schedule, 2010 (210B file). Available at: Http://www.cms.gov/pfslookup/02-PFSsearch.asp [Last accessed 28 February 2011]
34. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: Implications for control through routine immunization. J Med Virol 2003;70(Suppl 1):S111-18
35. Centers for Disease Control and Prevention. National diabetes fact sheet: General information and national estimates on diabetes in the United States, 2007. Atlanta, GA, USA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008
36. Multiple sclerosis-natalizumab: Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis. National Institute for Health and Clinical Excellence (NICE), August 2007. Available at: Http://www.nice.org.uk/Guidance/TA127 [Last accessed 28 February 2011]
37. Fox EJ. Emerging oral agents for multiple sclerosis. Am J Manag Care 2010;16:S219-S26
38. Lipsy R. Will the newer oral MS agents be welcomed by managed care organizations? Am J Manag Care 2010;16:S227-S33
39. Treadway K, Cutter G, Salter A, et al. Factors that influence adherence with the disease-modifying therapy in MS. J Neurol 2009;256:568-76
40. Rao SM. Neuropsychology of multiple sclerosis. Curr Opin Neurol 1995;8:216-20
41. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-8
42. Young PJ, Lederer C, Eder K, et al. Sylvia Lawry Centre for Multiple Sclerosis Research. Relapses and subsequent worsening of disability in relapsing- remitting multiple sclerosis. Neurology 2006;67:804-8
43. American Academy of Neurology Guidelines 2002. Available at: Http://www.aan.com/go/practice/guidelines [Last accessed 28 February 2011]